Tenofovir disoproxil fumarate
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2001
- First approval year
- 2001
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Tenofovir disoproxil fumarate
- Molecular weight
- 635.52
- Structure (SMILES)
- CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C.O=C(O)/C=C/C(=O)O
- tenofovir disoproxil fumarate
- Tenofovir disoproxil fumarate
- tenofovir disoproxil fumarate component of atripla
- Tenofovir disoproxil fumarate component of atripla
- tenofovir disoproxil fumarate component of cimduo
- Tenofovir disoproxil fumarate component of cimduo
- tenofovir disoproxil fumarate component of complera
- Tenofovir disoproxil fumarate component of complera
- tenofovir disoproxil fumarate component of delstrigo
- Tenofovir disoproxil fumarate component of delstrigo
- tenofovir disoproxil fumarate component of eviplera
- Tenofovir disoproxil fumarate component of eviplera
- tenofovir disoproxil fumarate component of odefsey
- Tenofovir disoproxil fumarate component of odefsey
- tenofovir disoproxil fumarate component of stribild
- Tenofovir disoproxil fumarate component of stribild
- tenofovir disoproxil fumarate component of symfi
- Tenofovir disoproxil fumarate component of symfi
- tenofovir disoproxil fumarate component of temixys
- Tenofovir disoproxil fumarate component of temixys
- tenofovir disoproxil fumarate component of truvada
- Tenofovir disoproxil fumarate component of truvada
- viread
- Viread
- (R)-5-((2-(6-AMINO-9H-PURIN-9-YL)-1-METHYLETHOXY)METHYL)-2,4,6,8-TETRAOXA-5-PHOSPHANONANEDIOIC ACID, BIS(1-METHYLETHYL) ESTER, 5-OXIDE, (E)-2-BUTENEDIOATE (1:1)
- 9 r 2 bis isopropoxycarbonyl oxy methoxy phosphinyl methoxy propyl adenine fumarate 1 1
- 9-((R)-2-((BIS(((ISOPROPOXYCARBONYL)OXY)-METHOXY)PHOSPHINYL)METHOXY)PROPYL)ADENINE FUMARATE (1:1)
- 9-((R)-2-((BIS(((ISOPROPOXYCARBONYL)OXY)METHOXY)PHOSPHINYL)METHOXY)PROPYL)ADENINE FUMARATE (1:1)
- atripla component tenofovir disoproxil fumarate
- ATRIPLA COMPONENT TENOFOVIR DISOPROXIL FUMARATE
- bis hydroxymethyl r 2 6 amino 9h purin 9 yl 1 methylethoxy methyl phosphonate bis isopropyl carbonate ester fumarate 1 1
- Bis(hydroxymethyl) [[(R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]phosphonate, bis(isopropyl carbonate) (ester), fumarate (1:1)
- delstrigo component tenofovir disoproxil fumarate
- DELSTRIGO COMPONENT TENOFOVIR DISOPROXIL FUMARATE
- dolutegravir dtg 50 mg orally bid 12 hours apart plus tdf 3tc
- Entecavir；Tenofovir Disoproxil Fumarate (TDF)； Tenofovir alafenamide fumarate (TAF)；Interferons
- eviplera component tenofovir disoproxil fumarate
- EVIPLERA COMPONENT TENOFOVIR DISOPROXIL FUMARATE
- gs 4331 05
- GS-4331-05
- GS-4331-05-
- gsk 548470
- GSK-548470
- gsk548470
- GSK548470
- GSK548470 300 mg tablet
- odefsey component tenofovir disoproxil fumarate
- ODEFSEY COMPONENT TENOFOVIR DISOPROXIL FUMARATE
- pmpa prodrug
And 55 more, listed on the interactive page.
- CAS registry numbers
- 202138-50-9
- ChEMBL ID
- CHEMBL1486
- InChIKey
- VCMJCVGFSROFHV-WZGZYPNHSA-N
- PubChem compound IDs
- 6398764
- RxNorm IDs (RxCUI)
- 322248
- FDA ingredient codes (UNII)
- OTT9J7900I
- Applicant
- GILEAD SCIENCES INC
- Approval date
- 26 Oct 2001
- Application number
- NDA021356
- Patents
- 0
- Designations
- 4
- First in class
- No
- Fast track
- Yes
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- Yes
- Orphan exclusivity
- No
- Accelerated approval
- Yes
- Availability
- Prescription only
- Boxed warning
- Yes
- Drug name stem
- -vir
Administration routes
- Oral
Mechanisms of action
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase inhibitor
- Action type
- Inhibitor
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Protein identifier
- Q72547
Open Targets mechanisms
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase inhibitor
- Action type
- Inhibitor
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Condition
- HIV Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000180
- Subject identifier
- D015658
- Condition
- Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Lymphoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- HIV Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000764
- Subject identifier
- D015658
- Condition
- Acquired Immunodeficiency Syndrome
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000765
- Subject identifier
- D000163
- Condition
- Liver Diseases
- Highest recorded phase
- 4
- Condition identifier
- EFO:0001421
- Subject identifier
- D008107
- Condition
- Insulin Resistance
- Highest recorded phase
- 1
- Condition identifier
- EFO:0002614
- Subject identifier
- D007333
- Condition
- Hepatitis C
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003047
- Subject identifier
- D006526
- Condition
- Hepatitis B, Chronic
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004197
- Subject identifier
- D019694
- Condition
- Hepatitis B, Chronic
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004239
- Subject identifier
- D019694
- Condition
- Communicable Diseases
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005741
- Subject identifier
- D003141
- Condition
- Hepatitis D
- Highest recorded phase
- 2
- Condition identifier
- EFO:0007304
- Subject identifier
- D003699
- Condition
- Hepatitis, Chronic
- Highest recorded phase
- 1
- Condition identifier
- EFO:0008496
- Subject identifier
- D006521
- Condition
- Lipodystrophy
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000727
- Subject identifier
- D008060
- Condition
- Liver Cirrhosis, Biliary
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001486
- Subject identifier
- D008105
- Condition
- Parkinson Disease
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0005180
- Subject identifier
- D010300
- Condition
- Multiple Sclerosis
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0005301
- Subject identifier
- D009103
- Condition
- Tuberculosis
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0018076
- Subject identifier
- D014376
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- EFO_0000180
- Condition identifier
- EFO_0000180
- Highest recorded phase
- 4
- Condition identifier
- EFO_0000544
- Condition identifier
- EFO_0000544
- Highest recorded phase
- 4
- Condition identifier
- EFO_0000764
- Condition identifier
- EFO_0000765
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001421
- Condition identifier
- EFO_0003884
- Condition identifier
- EFO_0004197
- Condition identifier
- EFO_0004239
- Condition identifier
- EFO_0007949
- Condition identifier
- EFO_0008496
- Highest recorded phase
- 1
- Condition identifier
- EFO_0009878
- Condition identifier
- EFO_0010125
- Highest recorded phase
- 3
- Condition identifier
- EFO_0010702
- Condition identifier
- EFO_1000727
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001486
- Highest recorded phase
- 2
- Condition identifier
- HP_0001394
- Condition identifier
- HP_0001395
- Condition identifier
- HP_0001410
- Condition identifier
- HP_0001410
- Highest recorded phase
- 4
- Condition identifier
- HP_0001513
- Highest recorded phase
- 3
- Condition identifier
- HP_0003124
- Highest recorded phase
- 2
- Condition identifier
- HP_0004324
- Condition identifier
- HP_0025502
- Highest recorded phase
- 3
And 23 more, listed on the interactive page.
- Warning
- Black Box Warning
- Effect
- hepatotoxicity
- Warning
- Black Box Warning
- Effect
- immune system toxicity
- Warning
- Black Box Warning
- Effect
- hepatotoxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- immune system toxicity
- Country
- United States
- Event
- abortion spontaneous
- Reports
- 592
- Reporting signal score
- 782.556
- Event
- acute hiv infection
- Reports
- 66
- Reporting signal score
- 273.854
- Event
- blood creatinine increased
- Reports
- 541
- Reporting signal score
- 503.828
- Event
- blood hiv rna increased
- Reports
- 175
- Reporting signal score
- 579.656
- Event
- blood phosphorus decreased
- Reports
- 125
- Reporting signal score
- 270.933
- Event
- csf hiv escape syndrome
- Reports
- 76
- Reporting signal score
- 333.089
- Event
- drug resistance
- Reports
- 802
- Reporting signal score
- 1,670.1
- Event
- fanconi syndrome
- Reports
- 187
- Reporting signal score
- 604.07
- Event
- fanconi syndrome acquired
- Reports
- 337
- Reporting signal score
- 1,245.11
- Event
- genotype drug resistance test positive
- Reports
- 145
- Reporting signal score
- 424.538
- Event
- glycosuria
- Reports
- 121
- Reporting signal score
- 364.358
- Event
- hepatitis b
- Reports
- 166
- Reporting signal score
- 319.655
- Event
- hepatitis b dna increased
- Reports
- 81
- Reporting signal score
- 250
- Event
- hypophosphataemia
- Reports
- 244
- Reporting signal score
- 505.907
- Event
- immune reconstitution inflammatory syndrome
- Reports
- 373
- Reporting signal score
- 971.537
- Event
- immune reconstitution syndrome
- Reports
- 111
- Reporting signal score
- 321.897
- Event
- lipodystrophy acquired
- Reports
- 260
- Reporting signal score
- 836.187
- Event
- mitochondrial toxicity
- Reports
- 154
- Reporting signal score
- 576.697
- Event
- nephropathy toxic
- Reports
- 272
- Reporting signal score
- 469.588
- Event
- osteomalacia
- Reports
- 114
- Reporting signal score
- 320.814
- Event
- osteoporosis
- Reports
- 559
- Reporting signal score
- 1,139.05
- Event
- pathogen resistance
- Reports
- 518
- Reporting signal score
- 1,373.75
- Event
- premature baby
- Reports
- 355
- Reporting signal score
- 396.271
- Event
- premature delivery
- Reports
- 226
- Reporting signal score
- 293.869
- Event
- progressive external ophthalmoplegia
- Reports
- 72
- Reporting signal score
- 323.508
And 9 more, listed on the interactive page.
- NCT00002396
- NCT00002415
- NCT00002450
- NCT00007436
- NCT00024986
- NCT00027339
- NCT00035932
- NCT00036452
- NCT00036634
- NCT00038220
- NCT00039741
- NCT00043966
- NCT00046033
- NCT00050895
- NCT00074581
- NCT00076791
- NCT00078182
- NCT00084136
- NCT00089505
- NCT00090779
- NCT00099632
- NCT00100048
- NCT00102206
- NCT00105079
- NCT00106379
And 323 more, listed on the interactive page.
- Dose
- 300mg
- Route
- Oral
- How often
- Once daily
- Hydrogen bond acceptors
- 15
- Hydrogen bond donors
- 1
- Polar surface area
- 185.44
- Calculated partition coefficient (ALogP)
- 3.04
- Prodrug
- Yes
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 13
- Heavy atoms
- 43
- Molecular formula
- C23H34N5O14P
- Monoisotopic mass
- 635.18398777
- Natural product
- No
- 0006-5007
- 0093-5234
- 0093-7704
- 0378-5440
- 0904-6821
- 0904-7172
- 16714-534
- 16714-820
- 31722-535
- 31722-560
- 31722-736
- 33342-096
- 33342-106
- 33342-138
- 42291-800
- 42291-980
- 42385-801
- 42385-915
- 42385-928
- 42385-929
- 42385-953
- 42543-719
- 49502-450
- 49502-475
- 50268-758
And 65 more, listed on the interactive page.
- Recorded assays
- 746
- Active assays
- 63
- Confirmatory
- Screening
- Summary
- Anti-HIV Agents
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.
- Antiviral Agents
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.
- Reverse Transcriptase Inhibitors
Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template.
Oral bioavailability
- Median
- 3.4
- Mean
- 3.4
- Minimum
- 3.4
- Maximum
- 3.4
- Unit
- %
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (443)
- 'Tenofovir Pulse and Peg Interferon Alpha 2b' Therapy in HBeAg-positive Patients With Normal ALT
- A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
- A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B
- A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment
- A Comparison of Adefovir and Tenofovir for the Treatment of Lamivudine-Resistant Hepatitis B Virus in People With HIV
- A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy
- A Compassionate Use Study of Tenofovir Disoproxil Fumarate as Treatment for HIV Infection
- A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients
- A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs
- A Drug Safety and Dose-exploratory Clinical Study of Azvudine Tablets in Patients Who Have Not Received Anti-HIV Treatment
- A Drug-drug Interaction (DDI) Study of Morphothiadine Mesilate/Ritonavir in Healthy Subjects
- A Key Link for Transmission Prevention
- A Pharmacist-run PrEP Program for Women
- A Pharmacokinetic Evaluation of Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis in Transgender Women
- A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B
- A phase4 Clinical Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Disoproxil From Tenofovir Disoproxil Fumarate in Patients With Chronic Hepatitis B
- A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-Risk Populations in Kenya, Africa
- A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-risk Populations in Uganda, Africa
- A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection
- A Randomized Controlled Trial on the Efficacy of Tenofovir Disoproxil Fumarate (TDF)-Switch Therapy in Chronic Hepatitis B Patients With Incomplete Response to Entecavir
Approved for (4)
In development for (12)
- AIDS Phase 3
- COVID-19 Phase 3
- Hepatitis Phase 1
- Hepatitis C virus infection Phase 1
- Hepatitis D virus infection Phase 2
- Infectious disease Phase 2
- Lipodystrophy Phase 2
- Lymphoma Phase 1
- Multiple sclerosis Phase 2
- Parkinson disease Phase 1
- Primary biliary cholangitis Phase 2
- Tuberculosis Phase 1